Back to feed

NCT00128856

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Phase II Pharmacogenomic and Clinical Trial for the Administration of Gemcitabine-doxorubicin-paclitaxel (GAT) as Neoadjuvant Treatment of Patients With Stage III Breast Cancer

ClinicalTrials.gov
Sponsor
Spanish Breast Cancer Research Group
Status
Completed
Versions
5
Adjacent patches
4
Severity is deterministic, reproducible, uncalibrated triage metadata, not validated review priority or proven wrongdoing. New Evidence Record packages are generated for deterministic event-class membership, not by triage rank alone.

Material event timeline

3 shown
Triage: High
2005-08-29
Secondary Outcome Change
v0 to v1 Post Recruitment Inspect patch
/protocolSection/contactsLocationsModule/overallOfficials/0/name
/protocolSection/contactsLocationsModule/overallOfficials/1/name
/protocolSection/descriptionModule/briefSummary
Triage: Critical
2018-03-15
Primary Outcome Change
v1 to v2 Post Recruitment Inspect patch Evidence Record
/protocolSection/armsInterventionsModule/armGroups
/protocolSection/armsInterventionsModule/interventions/0/armGroupLabels
/protocolSection/armsInterventionsModule/interventions/0/otherNames
Triage: Critical
2018-12-13
Primary Outcome Change
v2 to v3 Post Recruitment Inspect patch Evidence Record
/protocolSection/armsInterventionsModule/armGroups/0/description
/protocolSection/armsInterventionsModule/armGroups/0/interventionNames/0
/protocolSection/armsInterventionsModule/armGroups/0/interventionNames/1